Muscle Training Induced Angiogenesis in COPD

COPD Clinical Trial

— COPDµvasc  

Official title:

Impact of Exercise Training on Skeletal Muscle Capillary Maturation During Angiogenesis in COPD Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02040363
• Other study ID #: 9224
• Status: Completed
• Phase: N/A
• Start date: January 2014
• Est. completion date: August 2016

Study information

• Verified date: January 2020
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

COPD patients experiment a peripheral muscle dysfunction which impact their exercise tolerance and health-related quality of life. The capillary to fiber interface is reduced and impact the exercise capacity of the patients. While the muscle capillary creation in response to exercise training is blunted in COPD patients, the maturation of the neo-capillaries could also be blunted and contribute to the impaired aniogionenesis in patients. Because the capillary maturation is a sensitive and dynamic process, only different modalities of exercise training and multiple time-points of measures would allow to capture this microvascular adaptation.

Aim of the study : Compare the muscle capillary maturation in response to training at 5 and 10 weeks, in sedentary healthy subject trained at the intensity of the ventilatory threshold (60-65% of VO2max), versus :- COPD patients trained at a similar intensity (60-65% of VO2max)- COPD patients trained at a similar absolute intensity (90% of VO2max).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: August 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 78 Years

Eligibility

Inclusion Criteria:

• COPD patients :

• FEV1<80%pred.

• non exacerbation during the past 4 weeks

• no oxygen therapy, -

Healthy subjects:

• <150min/week of moderate-to-vigorous physical activity,

• Voorrips score <9

Exclusion Criteria:

• Unstable comorbidity

• Long term oxygen therapy or ventilation

• Rehabilitation program during the past 12 months

• nutritional supplementation during the past 4 weeks

• allopurinol or N-acetylcystein during the past 4 weeks

• long corticosteroid treatment during the past 6 months

• hyperreactivity to xylocain

• anticoagulant or platelet aggregation inhibitors treatment

• participation to an other research study-pregnancy or impossibility to provide informed consent, ...

Related Conditions & MeSH terms

• COPD
• Peripheral Muscle Dysfunction

Intervention

Procedure:
• Muscular biopsy

Other:
• 5-10 weeks sport training

Locations

Country	Name	City	State
France	Department of clinical Physiology - University Hospital	Montpellier

Sponsors (4)

Lead Sponsor	Collaborator
University Hospital, Montpellier	5 Santé, Institut National de la Santé Et de la Recherche Médicale, France, Université Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Capillary-o-fiber ratio assessed by immunochemistry on a muscle biopsy of the vastus lateralis of the quadriceps		5 weeks
Primary	Capillary-o-fiber ratio assessed by immunochemistry on a muscle biopsy of the vastus lateralis of the quadriceps		10 weeks
Secondary	quadriceps endurance		5 weeks
Secondary	quadriceps endurance		10 weeks
Secondary	Pericyte coverage of skeletal muscles capillaries assessed by immunostaining of a muscle biopsy of the vastus lateralis of the quadriceps		5 weeks
Secondary	Pericyte coverage of skeletal muscles capillaries assessed by immunostaining of a muscle biopsy of the vastus lateralis of the quadriceps		10 weeks
Secondary	Effect of the serum of COPD patients and SHS on pericyte morphology and in vitro		10 weeks
Secondary	Effect of the serum of COPD patients and SHS on pericyte/endothelial cells interactions in vitro		10 weeks
Secondary	Effect of the serum of COPD patients and SHS on pericyte/endothelial cells interactions in vivo		10 weeks